Switching from selexipag to inhaled treprostinil for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed diagnosis of pulmonary arterial hypertension (PAH) through a heart catheterization test.
- You have been taking selexipag (200 to 1600 mcg twice daily) for at least 90 days, but you are not satisfied with the results or you have side effects.
- You can be on up to two other PAH medicines (not including prostacyclins) as long as the doses stay the same during the study.
- Your symptoms are mild to moderate (Class II or III on the New York Heart Association scale).
- You are able to use a dry powder inhaler correctly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This study looks at how patients feel and how well they stick to treatment when switching from an inhaled medication (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (high blood pressure in the lungs). If you are already switching, your experiences can help doctors understand the benefits and challenges of this change.
This study looks at how well treprostinil, a medication given by injection, works for people with pulmonary hypertension. It aims to gather real-world data to understand treatment trends and outcomes.
This study tests a new drug, tiprelestat, added to your current treatment for pulmonary arterial hypertension (PAH). It aims to see if it improves your symptoms and exercise ability.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.